By the end of this session, attendees will be able to:

• List two (2) major strategies employed for delivering a robust personalized medicine supply chain
• Identify at least two (2) concerns in the handling of cell and gene therapy clinical materials
• Describe potential labeling solutions appropriate to the labeling of cell and gene therapy products for transport
• Create better outcomes for patients via the creation of a robust supply chain